PURPOSE: To assess the prevalence of depression among low-income, ethnic minority women with breast or gynecologic cancer, receipt of antidepressant medications or counseling services, and correlates of depression. PATIENTS AND METHODS: Study patients were 472 women receiving cancer care in an urban public medical center. Women had a primary diagnosis of breast (stage 0 to III) or gynecologic cancer (International Federation of Gynecology and Obstetrics stage 0 to IIIB). A diagnostic depression screen and baseline questionnaire were administered before or during active treatment or during active follow-up. Self-report data were collected on receipt of depression treatment, use of supportive counseling, pain and receipt of pain medication, functional status and well-being, and perceived barriers to cancer care. RESULTS: Twenty-four percent of women reported moderate to severe levels of depressive disorder (30% of breast cancer patients and 17% of gynecologic cancer patients). Only 12% of women meeting criteria for major depression reported currently receiving medications for depression, and only 5% of women reported seeing a counselor or participating in a cancer support group. Neither cancer stage nor treatment status was correlated with depression. Primary diagnosis of breast cancer, younger age, greater functional impairment, poorer social and family well-being, anxiety, comorbid arthritis, and fears about treatment side effects were correlated with depression. CONCLUSION: Findings indicate that depressive disorder among ethnic minority, low-income women with breast or gynecologic cancer is prevalent and is correlated with pain, anxiety, and health-related quality of life. Because these women are unlikely to receive depression treatment or supportive counseling, there is a need for routine screening, evaluation, and treatment in this population.
RCT Entities:
PURPOSE: To assess the prevalence of depression among low-income, ethnic minority women with breast or gynecologic cancer, receipt of antidepressant medications or counseling services, and correlates of depression. PATIENTS AND METHODS: Study patients were 472 women receiving cancer care in an urban public medical center. Women had a primary diagnosis of breast (stage 0 to III) or gynecologic cancer (International Federation of Gynecology and Obstetrics stage 0 to IIIB). A diagnostic depression screen and baseline questionnaire were administered before or during active treatment or during active follow-up. Self-report data were collected on receipt of depression treatment, use of supportive counseling, pain and receipt of pain medication, functional status and well-being, and perceived barriers to cancer care. RESULTS: Twenty-four percent of women reported moderate to severe levels of depressive disorder (30% of breast cancerpatients and 17% of gynecologic cancerpatients). Only 12% of women meeting criteria for major depression reported currently receiving medications for depression, and only 5% of women reported seeing a counselor or participating in a cancer support group. Neither cancer stage nor treatment status was correlated with depression. Primary diagnosis of breast cancer, younger age, greater functional impairment, poorer social and family well-being, anxiety, comorbid arthritis, and fears about treatment side effects were correlated with depression. CONCLUSION: Findings indicate that depressive disorder among ethnic minority, low-income women with breast or gynecologic cancer is prevalent and is correlated with pain, anxiety, and health-related quality of life. Because these women are unlikely to receive depression treatment or supportive counseling, there is a need for routine screening, evaluation, and treatment in this population.
Authors: D Bodurka-Bevers; K Basen-Engquist; C L Carmack; M A Fitzgerald; J K Wolf; C de Moor; D M Gershenson Journal: Gynecol Oncol Date: 2000-09 Impact factor: 5.482
Authors: M B Keller; J P McCullough; D N Klein; B Arnow; D L Dunner; A J Gelenberg; J C Markowitz; C B Nemeroff; J M Russell; M E Thase; M H Trivedi; J Zajecka Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245
Authors: K O Anderson; T R Mendoza; V Valero; S P Richman; C Russell; J Hurley; C DeLeon; P Washington; G Palos; R Payne; C S Cleeland Journal: Cancer Date: 2000-04-15 Impact factor: 6.860
Authors: Laura P Forsythe; Catherine M Alfano; Corinne R Leach; Patricia A Ganz; Michael E Stefanek; Julia H Rowland Journal: J Clin Oncol Date: 2012-07-09 Impact factor: 44.544
Authors: Charles L Shapiro; Mary S McCabe; Karen L Syrjala; Debra Friedman; Linda A Jacobs; Patricia A Ganz; Lisa Diller; Marci Campell; Kathryn Orcena; Alfred C Marcus Journal: J Cancer Surviv Date: 2009-01-24 Impact factor: 4.442
Authors: K Ebenhan; K Leuteritz; Y Barthel; M E Beutel; K Papsdorf; G Weissflog; E Brähler Journal: Geburtshilfe Frauenheilkd Date: 2013-08 Impact factor: 2.915